EUVIMEDEUVIMED entdecken
Crossref

Association of BNT162b2 SARS ‐ CoV ‐2 vaccination during pregnancy with postnatal outcomes in premature infants

Liran Tamir-Hostovsky iD, Ayala Maayan-Metzger, Ayelet Gavri-Beker, Douglas Watson, Leah Leibovitch, Tzipi Strauss

Acta Paediatrica · 2024

DOI: 10.1111/apa.17329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Paediatrica, 2024. Verfasst von Liran Tamir-Hostovsky und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel. Hauptthemen laut MEDLINE: Infant, Premature, BNT162 Vaccine. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The effect of COVID‐19 vaccine given during pregnancy on premature infants is unknown. This study aims to determine the association between maternal COVID‐19 vaccine with postnatal outcome in premature infants.

Methods

This is a single‐centre retrospective case–control study of infants born before 35 weeks gestation to mothers who received SARS‐CoV‐2 vaccine during pregnancy compared with infant born to non‐vaccinated mothers.

Results

A total of 78 infants in each group were included. Infants in the vaccinated group had less respiratory distress syndrome (RDS) ( p = 0.02) and less need for respiratory support ( p = 0.002), and maternal vaccine had a protective effect on RDS [adjustable OR 0.38 (0.17–0.85)]. Vaccination during the first compared to the second trimester was associated with earlier gestational age (32.3 ± 2.1 vs. 33.3 ± 1.1 weeks, p = 0.03).

Conclusion

We demonstrated that maternal SARS‐CoV‐2 vaccine is not associated with postnatal adverse effect in premature infants and potentially has a protective effect on RDS. Earlier gestational age among the infants born to mothers who received COVID‐19 vaccine during the first trimester did not translate to higher rate of postnatal complications. These findings might suggest that COVID‐19 vaccine is safe in high‐risk pregnancies, but timing of administration should be considered. Further studies are needed to confirm our findings and the biological mechanism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Infant, PrematureBNT162 VaccineHumansFemalePregnancyRetrospective StudiesInfant, NewbornCase-Control StudiesAdultCOVID-19 VaccinesMaleCOVID-19Pregnancy Complications, InfectiousRespiratory Distress Syndrome, NewbornVaccination

Stichwörter der Autor:innen

COVID‐19 vaccinepostnatal outcomeprematurityrespiratory distress syndrome

Substanzen

BNT162 VaccineCOVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Neonatology, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel.
  • Faculty of Medical and Health Science, Tel-Aviv University, Tel-Hashomer, Israel.
  • Department of Infectious Diseases, The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Liran Tamir-Hostovsky

Zitieren

APA

Tamir-Hostovsky, L., Maayan-Metzger, A., Gavri-Beker, A., Watson, D., Leibovitch, L., & Strauss, T. (2024). Association of BNT162b2 SARS ‐ CoV ‐2 vaccination during pregnancy with postnatal outcomes in premature infants. Acta Paediatrica. https://doi.org/10.1111/apa.17329

Vancouver

Tamir-Hostovsky L, Maayan-Metzger A, Gavri-Beker A, Watson D, Leibovitch L, Strauss T. Association of BNT162b2 SARS ‐ CoV ‐2 vaccination during pregnancy with postnatal outcomes in premature infants. Acta Paediatrica. 2024. doi:10.1111/apa.17329

BibTeX
@article{TamirHostovsky2024,
  author = {Tamir-Hostovsky, Liran and Maayan-Metzger, Ayala and Gavri-Beker, Ayelet and Watson, Douglas and Leibovitch, Leah and Strauss, Tzipi},
  title = {Association of BNT162b2 SARS ‐ CoV ‐2 vaccination during pregnancy with postnatal outcomes in premature infants},
  journal = {Acta Paediatrica},
  year = {2024},
  doi = {10.1111/apa.17329}
}
Kostenlos starten →